ArticleEuropean journal of nuclear medicine and molecular imaging2024
Theranostic role of
Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- The Vascular Density/Angiogenesis Marker CD31/PECAM1 does not Correlate with Overall Survival in Neuroendocrine Tumors.Journal of gastrointestinal cancer · 2026Article
- ImmunoPET imaging of Trop2 expression in triple-negative breast cancer using [European journal of nuclear medicine and molecular imaging · 2025Article
- Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody-drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer.European journal of nuclear medicine and molecular imaging · 2025Article
- A Novel Theranostic Strategy for Malignant Pulmonary Nodules by Targeted CECAM6 withAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- ImmunoPET Imaging of Trop2 Expression in Bladder Cancer Using [Molecular pharmaceutics · 2025Article
- Preclinical evaluation of 64Cu/177Lu-labelled anti-CD30 monoclonal antibody for theranostics in CD30-positive lymphoma.European journal of nuclear medicine and molecular imaging · 2025Article
- CD38-specific immunoPET imaging for multiple myeloma diagnosis and therapeutic monitoring: preclinical and first-in-human studies.European journal of nuclear medicine and molecular imaging · 2025Article
- Discovery of a highly specific radiolabeled antibody targeting B-cell maturation antigen: Applications in PET imaging of multiple myeloma.European journal of nuclear medicine and molecular imaging · 2025Article
- [American journal of nuclear medicine and molecular imaging · 2025Article
- Novel Molecular Classification of Breast Cancer with PET Imaging.Medicina (Kaunas, Lithuania) · 2024Review
- Repurposing propofol for breast cancer therapy through promoting apoptosis and arresting cell cycle.Oncology reports · 2024Article
- [European journal of nuclear medicine and molecular imaging · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTriple-negative breast cancer (TNBC) has a poor prognosis due to the absence of effective therapeutic targets. Vascular endothelial growth factor (VEGF) family are expressed in 30-60% of TNBC, therefore providing potential therapeutic targets for TNBC. Aflibercept (Abe), a humanized recombinant fusion protein specifically bound to VEGF-A, B and placental growth factor (PIGF), has proven to be effective in the treatment in some cancers. Therefore,
methodsAbe was radiolabeled with
resultsFITC-labeled Abe showed a strong binding affinity to VEGF in TNBC 4T1 cells and HUVECs by flow cytometry and cell immunofluorescence. Tumor uptake of
conclusion
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.